I-31: New Treatment in PCOS

author

Abstract:

as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have marked insulin resistance, independent of obesity. Prolonged (6 months) medical therapy for hirsutism is necessary to document effectiveness . Many drugs used for the treatment of hirsutism are not FDA approved for this indication. No effective treatment for alopecia is known. Anti-androgens should not be used without effective contraception. Flutamide is of limited value because of its dosedependent hepatotoxicity. Drospirenone in the dosage used in some OCs is not antiandrogenic. The best medical therapy and long of treatment for hirsutism is unclear. Measurement of serum androgens is fraught with error but is the best estimate we have for hyperandrogenism. Overall, the benefits of OCPs outweigh the risks in most patients with PCOS. Women with PCOS are more likely to have contraindications for OCP use than normal women. In the absence of other risk factors, there is no evidence that women with PCOS are at increased risk of cardiovascular disease (CVD) with OCP treatment compared with normal women. There is no evidence for differences in effectiveness and risk among the various progestogens and when used in combination with a 20 versus a 30 mg daily dose of estrogen. OCPs do not negatively affect subsequent fertility. There is no definitive evidence that the type of OCP determines efficacy of hirsutism control. Statins can reduce the concentration of total testosterone, Total Cholesterol, TG and LDL. However, it cannot be concluded that statins have long-term benefit. Efficacy and safety of newer drugs for treatment of type2 DM in PCOS (including GLP-1 agonists) is unclear. The efficacy of bariatric surgery and its long-term effect is unclear.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

I-47: ART Outcome in PCOS Patients

PCOS is still a problem in gynecology and infertility. Especially in ART the problem of PCOS patients is bigger and more highlighted. These patients are prone to over and under stimulation. Strategies to overcome hyper stimulation are: use of metformin, ovarian drilling, use of minimal stimulation, suppressing LH with use of OCP or GnRh analogues, use of GnRh antagonist in COH. But none of thes...

full text

I-31: New Approaches for Luteal Phase Support in ART Cycles

Background During a normal menstrual cycle, progesterone prepares the endometrium for pregnancy by stimulating proliferation in response to human chorionic Gnadotropin produced by the corpus luteum. Many questions were raised about the role of follicular fluid aspiration on the granuloma cells at the time of oocyte retrieving during the ART cycles. Authors believes that oocyte retrieval might d...

full text

I-31: ART Outcome in Endometrioma

Background: Our Background was to evaluate the effect of ovarian endometrioma on ovarian stimulation outcomes in Intra Cytoplasmic Sperm Injection (ICSI). Materials and Methods: In this prospective cohort study, we followed 103 patients underwent ICSI procedures at royan Institute during 10 month. The study group consisted of 46 women who had endometriomawith size more than 1 cm. The control gr...

full text

I-31: Antihistamine & Ovarian Hyperstimulation syndrome

Background: Ovarian hyperstimulation syndrome (OHSS) is a rare iatrogenic complication of ovulation stimulation. The pathogenesis of OHSS is uncertain. The crucial event appears to be an increase in capillary permeability by vasoactive mediators such as cytokine and histamine. The aim of this study is to evaluate the role of loratadine (antihistamine) in preventing ovarian hyperstimulation synd...

full text

I-31: The Scientific Underpinning of ART in Unexplained Infertility

Although intra uterine insemination (IUI) and in vitro fertilization (IVF) are widely accepted treatments among doctors and patients and practiced on large scale, it is good to realize that they have rarely been evaluated properly in randomized clinical trials or even in comparative cohort studies. Although the first pregnancy after IUI was established in 1884, it was not until 2008 that the fi...

full text

Clomiphene Resistant PCOS: Treatment Options

Clomiphene Citrate (Clomid, Serophene) was introduced into clinical medicine for the treatment of anovulation in the 1960’s. Its introduction represented a major breakthrough in the medical management for ovulation induction. Prior to Clomiphene, patients with PCOS who were anovulatory had few options besides weight loss and surgical wedge resection of the ovaries. While wedge resection was suc...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 7  issue 3

pages  14- 14

publication date 2013-09-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023